The landscape · Healthcare
Healthcare: what AI is really doing
Brief me in 2 minutes
AI in Healthcare.
Ambient scribes and comprehensive imaging triage are the two places AI now touches real money and real patients at scale, running in hundreds of health systems on paid contracts, and imaging just became the first AI diagnostic tool to get a Medicare add-on payment. Drug discovery and prior authorization are one step behind, funded heavily and running in production at specific customers but not yet proven at the scale their backers are pricing in. Patient facing chatbots are the wild card: adoption is enormous and mostly unsupervised, the safety regulator named that the top hazard in the field for 2026, and FDA's rulebook for generative AI devices is still a discussion paper whose comment window has just closed.
The game: we show you 6 things happening. You call each one real now, early or mostly hype. Then the receipts.
Shift 1 of 6
Ambient scribes go from pilot project to clinical infrastructure
Real now
Abridge alone is processing more than 50 million conversations a year across 150-plus health systems on paid contracts, that is deployment, not a demo.
How it works. A microphone in the exam room records the visit, and a model turns the conversation directly into a structured note inside Epic or Oracle Health, with the clinician editing rather than typing from scratch. Epic, the record system these tools write notes into, now ships its own built-in version, AI Charting, so the startups are selling into a platform that also competes with them.
Overstated: Vendors describe this as giving clinicians their time back. The receipts so far are about after hours charting going down, not about visit volume or patient outcomes changing.
Shift 2 of 6
Imaging AI moves from one algorithm per disease to one model reading the whole scan
Real now
This is FDA-cleared, already running in production reads, and as of October 1 Medicare pays an add-on for it; Viz.ai's clearances alone cover 1,700-plus hospitals.
How it works. Older radiology AI was a separate cleared product for each finding, one for pulmonary embolism, one for stroke. Aidoc's CARE foundation model reads a single abdominal CT for 14 conditions at once, and Viz.ai has stacked over 50 separate FDA clearances into one coordinated triage workflow across stroke, hemorrhage and aortic disease.
Overstated: The sensitivity and specificity numbers in the clearance are the trained validation cohort's numbers, not a guarantee of the same accuracy on the atypical case in front of a specific radiologist next Tuesday. And the add-on payment eases the cost of adopting the tool for eligible Medicare cases for three years; it is not proof the tool changes outcomes.
Shift 3 of 6
AI-designed drugs reach the Phase III test that actually decides the argument
Early
Money and molecules are real, but as of this writing no AI-discovered drug has an FDA approval, this segment is still waiting for its first proof point.
How it works. Over 173 AI-originated drug programs are now in clinical development, up from roughly two dozen in late 2023. Insilico Medicine's rentosertib, discovered and designed with generative AI, became the first such drug to reach Phase III, in idiopathic pulmonary fibrosis, and Isomorphic Labs raised $2.1 billion to keep its own drug design engine running.
Overstated: Pitches lean on the 80 to 90 percent Phase I success rate. That number is about safety, not efficacy, and the efficacy number, Phase II, is not currently beating the old way of doing things.
Shift 4 of 6
Payer AI starts reading prior authorization requests, with a proposed federal deadline pushing the plumbing to catch up
Early
Live at named customers with real accuracy numbers, but the federal rule that would force this across the whole industry wouldn't bite until October 2027.
How it works. AI models from vendors like Anterior and Cohere Health read the clinical note against the coverage policy and auto-clear requests that match, sending only the ambiguous cases to a nurse or physician. A 2026 CMS proposed rule would require payers to run this over standard FHIR APIs rather than fax and portals, with electronic prior authorization for drugs from October 2027.
Overstated: "AI never denies care" is the standard vendor line, describing where they've chosen to draw the product's scope now, not a technical ceiling on what the same model could be pointed at tomorrow.
Shift 5 of 6
Chatbots become the default first opinion for doctors and patients, largely unsupervised
Real now
Both sides of this are already at massive daily scale, this isn't a projection, it already happened.
How it works. OpenEvidence is a free, ad-supported clinical question answering tool built for physicians; in January its CEO, Daniel Nadler, claimed it was used by more than 40% of US doctors. Separately, tens of millions of ordinary patients ask general-purpose chatbots for medical advice with no clinical guardrails at all.
Overstated: OpenEvidence markets itself as built "for doctors," but a free, ad-supported model answering clinical questions is structurally the same product patients use unsupervised, just aimed at the users it describes as "verified physicians." Aiming it at doctors doesn't remove the hallucination risk underneath.
Shift 6 of 6
FDA starts drafting rules for generative AI devices after clearing over a thousand narrower ones under old rules
Early
The device clearances are real and already happening, but the actual rulebook for generative AI devices is still a closed comment window and a pilot, not a rule.
How it works. The FDA has cleared well over a thousand AI-enabled devices, almost all through the 510(k) pathway built for comparing a new device to an existing one. Generative and agentic AI devices, including foundation models like Aidoc's, don't fit that comparison cleanly, so in August 2026 FDA published a discussion paper asking how to evaluate them; the comment window closed October 19, 2026.
Overstated: This is explicitly a discussion paper, not a rule and not binding guidance, and TEMPO is a pilot, not an approval. Coverage calling either one FDA's new "AI regulation" is ahead of what the agency itself has said it is.
The scary part
What happens to jobs in Healthcare
What AI is already taking:
- Writing the visit note from the patient conversation Learning Health Systems (PMC) ↗
- First-pass reading of a CT scan for urgent, incidental findings PR Newswire (Aidoc) ↗
- Reviewing routine prior authorization requests against coverage policy PR Newswire (Anterior) ↗
- Looking up the current evidence for a clinical question at the point of care HLTH ↗
What stays human:
The physical exam, the procedure itself, and the conversation where a clinician tells someone their diagnosis are still entirely human, and no vendor in this briefing is trying to change that. What also stays human, by law rather than by choice, is the signature: courts and regulators are treating the physician's review of AI output as a duty that cannot be handed to the software.
Get better · 15 minutes
Fast, confident auditing of AI output under time pressure, the ability to spot the one wrong dose or missing negative in a note or a scan read before it reaches the patient, rather than rubber-stamping a document that reads as fluently as if you wrote it yourself.
Try this this week:
Pull one AI-drafted note or read from this week and grade it against ECRI's own hazard framing: check every medication dose, contraindication and negative finding against the source encounter rather than skimming for tone, and time how long that actually takes. That number, not the vendor's minutes-saved marketing figure, is your real workload.
Your move
Enterprise ambient scribing is now a four-way war between Abridge, Ambience, Microsoft's Nuance and Epic's own built-in AI Charting, don't enter it head-on. The open space is narrower: revenue-cycle and appeals automation on the payer side beyond prior auth intake, and agentic patient intake/triage, which is still mostly voice-agent demos, not deployed infrastructure.
Watch retention, not the headline note-drafting demo: Abridge citing over 90% of clinicians who start using the product still using it later is the tell that it works day to day. Watch reimbursement too: Aidoc's Medicare add-on payment is the first for an AI diagnostic, and a second one is what turns clearance into a budget line. Red flag in a drug-discovery pitch: any deck that quotes Phase I success rates without also giving you the Phase II number, since Phase II is where AI-discovered molecules are currently performing at ordinary industry rates, not better.
This quarter, pull ten ambient-scribe notes and compare them against your own memory or the recording, specifically hunting for omitted negatives (a symptom the patient denied that never made it into the note), not typos. That is the actual audit gap, and it's a fifteen-minute check per chart, not a research project.
The valuable skill now is fast, confident auditing of AI-generated clinical output, catching a wrong dose or a fabricated contraindication before it reaches a patient, since courts are already treating the physician's review as the point where responsibility sits. First step: read your specialty's entry on FDA's public AI-enabled device list so you know which tools in your own workflow are actually cleared versus just marketed as AI.
What's actually changing
- 1
Ambient scribes go from pilot project to clinical infrastructure
How it works. A microphone in the exam room records the visit, and a model turns the conversation directly into a structured note inside Epic or Oracle Health, with the clinician editing rather than typing from scratch. Epic, the record system these tools write notes into, now ships its own built-in version, AI Charting, so the startups are selling into a platform that also competes with them.
Why it matters. Less after hours charting for clinicians, but health systems are locking into a small number of vendors for a workflow that touches every visit, and one of those vendors is now the record system itself.
What's overstatedVendors describe this as giving clinicians their time back. The receipts so far are about after hours charting going down, not about visit volume or patient outcomes changing.
AbridgeAmbience HealthcareNuance DAX Copilot (Microsoft)SukiEpic
3 receipts
- Abridge's Series E blog post states the company supports over 50 million medical conversations a year across more than 150 health systems.
Abridge is now partnering with more than 150 enterprise health systems across the U.S.
Abridge, 23 June 2025 ↗ - Epic rolled out AI Charting, a built-in ambient documentation feature that listens during visits and drafts the note in its record system.
Epic Systems has rolled out AI Charting, a new built-in ambient documentation feature for its electronic health record platform
Digital Health News, 6 Feb 2026 ↗ - Early multi-site studies of ambient documentation show reduced after-hours charting rather than a headline productivity jump.
Early multicenter evaluations consistently show that ambient AI documentation reduces after‐hours charting, improves perceived documentation‐related well‐being, and may reduce clinician burnout at scale
Learning Health Systems (PMC), 10 Aug 2026 ↗
- Abridge's Series E blog post states the company supports over 50 million medical conversations a year across more than 150 health systems.
- 2
Imaging AI moves from one algorithm per disease to one model reading the whole scan
How it works. Older radiology AI was a separate cleared product for each finding, one for pulmonary embolism, one for stroke. Aidoc's CARE foundation model reads a single abdominal CT for 14 conditions at once, and Viz.ai has stacked over 50 separate FDA clearances into one coordinated triage workflow across stroke, hemorrhage and aortic disease. Since October 1, Medicare has let hospitals bill an add-on payment for eligible use of Aidoc's tool, the first time CMS has given that designation to an AI diagnostic.
Why it matters. Fewer incidental findings get missed and radiologists get one alert instead of fourteen separate tools pinging them, and hospitals now get partly reimbursed for it, but the diagnostic judgment for many conditions sits inside one company's model instead of being split across vendors.
What's overstatedThe sensitivity and specificity numbers in the clearance are the trained validation cohort's numbers, not a guarantee of the same accuracy on the atypical case in front of a specific radiologist next Tuesday. And the add-on payment eases the cost of adopting the tool for eligible Medicare cases for three years; it is not proof the tool changes outcomes.
AidocViz.ai
4 receipts
- CMS gave Aidoc's CARE Body CT Multi-Triage a New Technology Add-on Payment, the first such designation for an AI diagnostic tool.
This marks the first time CMS has granted NTAP designation for an AI-enabled diagnostic tool
Holland & Knight, 22 Sept 2026 ↗ - From October 1, 2026, hospitals can claim the add-on payment for using Aidoc's CARE Body CT Multi-Triage, and the payments continue for three years.
Beginning on October 1, 2026, hospitals will be eligible for NTAP reimbursement for use of Aidoc's CARE Body CT Multi-Triage technology. These supplemental payments will continue for three years.
Holland & Knight, 22 Sept 2026 ↗ - FDA cleared the tool to triage 14 critical findings in a single abdominal CT scan.
FDA has cleared a tool that can triage 14 critical findings in a single abdominal CT scan
STAT, 21 Jan 2026 ↗ - Viz.ai received the first and only FDA clearance for automatically quantifying subdural hemorrhage size on CT, adding to its stack of stroke and hemorrhage clearances.
Viz Subdural Plus, the first and only comprehensive solution for quantifying the size of collections like subdural hemorrhages (SDH)
Viz.ai, 12 June 2025 ↗
- CMS gave Aidoc's CARE Body CT Multi-Triage a New Technology Add-on Payment, the first such designation for an AI diagnostic tool.
- 3
AI-designed drugs reach the Phase III test that actually decides the argument
How it works. Over 173 AI-originated drug programs are now in clinical development, up from roughly two dozen in late 2023. Insilico Medicine's rentosertib, discovered and designed with generative AI, became the first such drug to reach Phase III, in idiopathic pulmonary fibrosis, and Isomorphic Labs raised $2.1 billion to keep its own drug design engine running.
Why it matters. Phase I success rates for AI-discovered molecules already beat historic pharma averages, but Phase I only tests safety. Phase II, which tests whether the drug works, is running at roughly the same success rate as ordinary drug discovery, so Phase III is the round that tells everyone if the AI premium is real.
What's overstatedPitches lean on the 80 to 90 percent Phase I success rate. That number is about safety, not efficacy, and the efficacy number, Phase II, is not currently beating the old way of doing things.
Insilico MedicineIsomorphic LabsChai Discovery
3 receipts
- Insilico Medicine dosed the first patient in the Phase III trial of rentosertib, describing it as the first Phase III trial of a generative AI-driven drug.
GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
Insilico Medicine, 10 Sept 2026 ↗ - The number of AI-designed drug programs in clinical development surged past 173 in early 2026, up from roughly two dozen in late 2023.
surged to over 173 in early 2026, up from roughly two dozen in late 2023
IntuitionLabs, 31 July 2026 ↗ - Isomorphic Labs raised $2.1 billion in a Series B round to scale its AI drug design engine and pipeline.
Isomorphic Labs announces it has raised $2.1 Billion in Series B funding.
Isomorphic Labs, 12 May 2026 ↗
- Insilico Medicine dosed the first patient in the Phase III trial of rentosertib, describing it as the first Phase III trial of a generative AI-driven drug.
- 4
Payer AI starts reading prior authorization requests, with a proposed federal deadline pushing the plumbing to catch up
How it works. AI models from vendors like Anterior and Cohere Health read the clinical note against the coverage policy and auto-clear requests that match, sending only the ambiguous cases to a nurse or physician. A 2026 CMS proposed rule would require payers to run this over standard FHIR APIs rather than fax and portals, with electronic prior authorization for drugs from October 2027.
Why it matters. This is the fix for the paperwork that the AMA says delays care for most physicians, but it also means an algorithm is now the first reader on a decision that can block a patient's treatment.
What's overstated"AI never denies care" is the standard vendor line, describing where they've chosen to draw the product's scope now, not a technical ceiling on what the same model could be pointed at tomorrow.
AnteriorCohere Health
2 receipts
- Anterior closed a $40 million round, bringing total funding to $64 million, reporting 99.24% clinical accuracy independently validated by KLAS Research and a 75% cut in review cycles at one customer.
99.24% clinical accuracy, independently validated by KLAS Research
PR Newswire (Anterior), 12 Feb 2026 ↗ - CMS's proposed rule would require payers to support electronic prior authorization for medical-benefit drugs over FHIR APIs starting October 2027.
CMS now proposes to require impacted payers to incorporate coverage and documentation requirements into those APIs to support the electronic prior authorization of drugs covered under a medical benefit beginning October 1, 2027.
CMS, 10 Apr 2026 ↗
- Anterior closed a $40 million round, bringing total funding to $64 million, reporting 99.24% clinical accuracy independently validated by KLAS Research and a 75% cut in review cycles at one customer.
- 5
Chatbots become the default first opinion for doctors and patients, largely unsupervised
How it works. OpenEvidence is a free, ad-supported clinical question answering tool built for physicians; in January its CEO, Daniel Nadler, claimed it was used by more than 40% of US doctors. Separately, tens of millions of ordinary patients ask general-purpose chatbots for medical advice with no clinical guardrails at all.
Why it matters. Adoption on both sides is real and fast, but the safety regulator ECRI just ranked chatbot misuse the top health technology hazard for 2026, and the first lawsuit over a chatbot's medical advice contributing to a patient's injury is now in court.
What's overstatedOpenEvidence markets itself as built "for doctors," but a free, ad-supported model answering clinical questions is structurally the same product patients use unsupervised, just aimed at the users it describes as "verified physicians." Aiming it at doctors doesn't remove the hallucination risk underneath.
OpenEvidenceHippocratic AI
4 receipts
- In January, OpenEvidence CEO Daniel Nadler claimed the platform was used by more than 40% of US physicians, HLTH reported.
Nadler claims the platform is now used by more than 40% of physicians in the U.S.
HLTH, 22 Jan 2026 ↗ - OpenEvidence is free to clinicians and sells pharmaceutical ads alongside its answers.
The platform is free to clinicians, sells pharmaceutical ads alongside its answers
AI Weekly, 21 Oct 2026 ↗ - ECRI named misuse of AI chatbots the number one health technology hazard of 2026, citing 40 million people a day turning to ChatGPT for health information.
More than 40 million people daily turn to ChatGPT for health information, according to a recent analysis from OpenAI.
ECRI, 21 Jan 2026 ↗ - A Florida man sued OpenAI alleging ChatGPT told him to stay 'recliner-bound' instead of seeking care for symptoms that preceded a near-fatal pulmonary embolism.
dismissed both sets of symptoms as relatively minor and suggested he stay home and remain "recliner-bound,"
CBS News, 23 July 2026 ↗
- In January, OpenEvidence CEO Daniel Nadler claimed the platform was used by more than 40% of US physicians, HLTH reported.
- 6
FDA starts drafting rules for generative AI devices after clearing over a thousand narrower ones under old rules
How it works. The FDA has cleared well over a thousand AI-enabled devices, almost all through the 510(k) pathway built for comparing a new device to an existing one. Generative and agentic AI devices, including foundation models like Aidoc's, don't fit that comparison cleanly, so in August 2026 FDA published a discussion paper asking how to evaluate them; the comment window closed October 19, 2026. In parallel, FDA's TEMPO pilot is letting some AI devices (four so far, including Cadence and Limbic) reach patients without marketing authorization.
Why it matters. Companies are already shipping foundation-model medical devices faster than the category built to evaluate them exists. What FDA decides now that the comment window has closed will set the evidence bar for the next wave of these products.
What's overstatedThis is explicitly a discussion paper, not a rule and not binding guidance, and TEMPO is a pilot, not an approval. Coverage calling either one FDA's new "AI regulation" is ahead of what the agency itself has said it is.
FDAAidocCadenceLimbic
3 receipts
- FDA's discussion paper asked for public feedback on evaluating generative AI-enabled medical devices by October 19, 2026.
DHCoE encourages feedback from device manufacturers, clinicians, researchers, the public, and other interested parties, to be submitted under docket number FDA-2026-N-7874 on Regulations.gov, by October 19, 2026.
FDA, 18 Aug 2026 ↗ - An independent tracker found that by late 2023 roughly 97% of cleared AI/ML devices used the 510(k) pathway, versus 2-3% via De Novo or PMA.
by late 2023 roughly 97% of cleared AI/ML devices used 510(k) (vs. 2-3% via De Novo or PMA)
IntuitionLabs, 26 Aug 2026 ↗ - FDA accepted four devices, including products from Cadence and Limbic, into its TEMPO pilot, which lets them reach the market without marketing authorization.
AI products from Cadence and Limbic are among four devices recently accepted into the agency’s TEMPO pilot program that will allow digital health companies to release their products without marketing authorization.
STAT, 3 Sept 2026 ↗
- FDA's discussion paper asked for public feedback on evaluating generative AI-enabled medical devices by October 19, 2026.
Who's doing it
10 companies to know, 8 with a round we can source. Newest first where dated.
Search these companies in the startup database ↗ · Explore all research tools
OpenEvidenceclinical decision support for physicians
Free, ad-supported question-answering tool for physicians to look up evidence-based clinical answers at the point of care.
Latest · 20 Oct 2026OpenEvidence and rival Doximity settled their lawsuit, dismissing all claims and counterclaims with each side paying its own costs. AI Weekly ↗
$250M Series D, 21 Jan 2026 source ↗
Aidocradiology triage AI
AI that flags urgent findings on CT scans for radiologists and care teams, now built on its own foundation model rather than one algorithm per condition.
Latest · 22 Sept 2026CMS gave Aidoc's CARE Body CT Multi-Triage a Medicare New Technology Add-on Payment, billable from October 1, 2026, for three years. Holland & Knight ↗
$150M Series E, 29 Apr 2026 source ↗
Insilico MedicineAI drug discovery
Uses generative AI to identify drug targets and design small-molecule drugs, running its own candidates through clinical trials.
Latest · 10 Sept 2026Dosed the first patient in Phase III of rentosertib for idiopathic pulmonary fibrosis, calling it the first Phase III trial of a generative-AI-driven drug. Insilico Medicine ↗
Chai DiscoveryAI molecular design
Builds foundation models trained on biochemical structures that let scientists design antibodies and small molecules computationally, licensed to pharma.
Latest · 20 Aug 2026Announced a collaboration with Bristol Myers Squibb to advance AI-driven antibody discovery, its fourth major pharma partnership of 2026. Chai Discovery ↗
$400M Series C, 14 July 2026 source ↗
Hippocratic AIpatient-facing voice agents
Voice AI agents for non-diagnostic, patient-facing work: post-discharge calls, chronic care check-ins, medication reminders, scheduling.
Latest · 13 Aug 2026Launched 'orchestrators', teams of voice agents run by a supervising model, backed by its Polaris safety system of a 700-billion-parameter model plus 30-plus supervising models. PR Newswire (Hippocratic AI) ↗
$444M cumulative to date, 13 Aug 2026 source ↗
Abridgeambient clinical documentation
Turns recorded doctor-patient conversations into structured clinical notes written directly into the EHR, for health systems.
Latest · 11 June 2026Abridge and NVIDIA are co-developing a foundation model for clinical conversations, alongside a strategic investment from Eli Lilly. Fortune ↗
$300M Series E, 23 June 2025 source ↗
Isomorphic LabsAI drug design
Alphabet-spinout drug design company that builds protein-structure and binding-affinity models to design drug candidates for pharma partners.
Latest · 12 May 2026Raised $2.1 billion in Series B funding, led by Thrive Capital with Alphabet, GV and new sovereign-wealth investors, to scale its drug design engine. Isomorphic Labs ↗
$2.1B Series B, 12 May 2026 source ↗
Anteriorpayer prior authorization AI
AI that reviews clinical documentation against coverage policy for health insurers to speed up prior authorization decisions.
Latest · 12 Feb 2026Closed a $40 million round, reporting 99.24% clinical accuracy independently validated by KLAS Research and a roughly 75% cut in review cycles at one customer. PR Newswire (Anterior) ↗
$40M undisclosed (total raised $64M), 12 Feb 2026 source ↗
Ambience Healthcareambient clinical documentation and coding
Ambient AI platform for documentation, medical coding and clinical documentation integrity across ambulatory, ED and inpatient settings.
Latest · 29 July 2025Raised $243 million in a Series C to scale its ambient documentation and coding platform for health systems. Ambience Healthcare ↗
$243M Series C, 29 July 2025 source ↗
Viz.aicare-coordination imaging AI
AI that detects time-critical findings like stroke and hemorrhage on imaging and automatically alerts the care team to coordinate treatment.
Latest · 12 June 2025Received the first and only FDA clearance for automatically quantifying subdural hemorrhage volume, thickness and midline shift on CT. Viz.ai ↗
Your move
Our read, built on the receipts above.
Enterprise ambient scribing is now a four-way war between Abridge, Ambience, Microsoft's Nuance and Epic's own built-in AI Charting, don't enter it head-on. The open space is narrower: revenue-cycle and appeals automation on the payer side beyond prior auth intake, and agentic patient intake/triage, which is still mostly voice-agent demos, not deployed infrastructure.
Watch retention, not the headline note-drafting demo: Abridge citing over 90% of clinicians who start using the product still using it later is the tell that it works day to day. Watch reimbursement too: Aidoc's Medicare add-on payment is the first for an AI diagnostic, and a second one is what turns clearance into a budget line. Red flag in a drug-discovery pitch: any deck that quotes Phase I success rates without also giving you the Phase II number, since Phase II is where AI-discovered molecules are currently performing at ordinary industry rates, not better.
This quarter, pull ten ambient-scribe notes and compare them against your own memory or the recording, specifically hunting for omitted negatives (a symptom the patient denied that never made it into the note), not typos. That is the actual audit gap, and it's a fifteen-minute check per chart, not a research project.
The valuable skill now is fast, confident auditing of AI-generated clinical output, catching a wrong dose or a fabricated contraindication before it reaches a patient, since courts are already treating the physician's review as the point where responsibility sits. First step: read your specialty's entry on FDA's public AI-enabled device list so you know which tools in your own workflow are actually cleared versus just marketed as AI.
What's next
- 1 Oct 2027 CMS's April 10 proposal would require impacted payers to support electronic prior authorization for medical-benefit drugs from this date cms.gov ↗
- Sept 2027 Primary endpoint window closes for Insilico's 52-week Phase III trial of rentosertib (GENESIS-IPF-3), the first AI-designed drug in Phase III insilico.com ↗
Other industries
- FinanceBanks move agentic AI from chatbots to running back-office and dealmaking work
- Software engineeringSpaceX owns Cursor and starts rewiring it: one Grok bundle, and OpenAI's models on the way out
- LegalLegal AI vendors go from research assistant to agent that produces the deliverable
- Real estateLeasing AI graduates from answering the phone to acting inside the property system
- Sales and marketingCustomers start sending their own AI agents, and vendors race to build the front door for them
- Jobs, HR and recruitingAI runs the first-round interview, not just the resume filter
- InsuranceClaims move from adjuster-first to AI-first, humans supervise the exceptions
- CybersecurityAttackers hand whole intrusion campaigns to AI agents, at about $50 a breach
- Consulting and accountingAI-written client reports become a recurring, public Big Four embarrassment
- Retail and e-commerceAgent checkout retreats to a cart, and the banks guard the last tap
- EducationNYC and LA ban AI for students, not for teachers
- Media and creativeAI video's money goes to the app that resells the models, not the lab that trains them
- Manufacturing and roboticsHumanoid robots move from demo livestreams to paid warehouse shifts
- Transport and robotaxisRobotaxis go from demo to metered fare, and Waymo starts borrowing to scale
- Energy and data-centre powerGrid rules get rewritten mid-buildout, state by state
- GovernmentGSA turns AI adoption into a government-wide subscription, then swaps 'free' for metered contracts
- Agriculture and foodDriverless tractors learn to run the tools behind them, through open platforms and retrofit kits